CORRELATION BETWEEN ACR TI-RADS CATEGORIES AND BETHESDA CYTOLOGY IN TI-RADS 4–5 THYROID NODULES AT LE VAN THINH HOSPITAL

Kim Thanh Từ1, , Lê Hoài Trần1, Thị Phi Yến Nguyễn1, Đình Hy Lê1, Thị Hồng Loan Huỳnh1
1 Bệnh viện Lê Văn Thịnh, TP. Hồ Chí Minh

Main Article Content

Abstract

Objectives: To describe the ultrasound features and Bethesda cytology of TI-RADS 4–5 thyroid nodules undergoing fine-needle aspiration (FNA) and to correlate ACR TI-RADS categories with Bethesda results.


Methods: A retrospective cross-sectional study of medical records of 306 patients (317 ultrasound-guided FNAs) with TI-RADS 4–5 nodules at Le Van Thinh Hospital from April 1 to September 1, 2026; cytology was classified by the 2023 Bethesda System.


Results: Mean age was 56.8 ± 13.1 years; 83.3% were women. TI-RADS 4 and TI-RADS 5 accounted for 73.2% and 26.8%. TI-RADS 5 nodules more often showed marked hypoechogenicity (76.2% vs 38.7%) and microcalcifications (49.4% vs 17.2%) (p < 0.001). Bethesda I, II, III–IV and V–VI accounted for 34.4%, 52.7%, 6.3% and 6.6%. Among 208 diagnostic samples, Bethesda V–VI was found in 26.4% of TI-RADS 5 versus 4.5% of TI-RADS 4 nodules; TI-RADS 5 was independently associated with Bethesda V–VI (adjusted OR 5.90; 95% CI 2.11–16.54), with a negative predictive value of 95.5%.


Conclusions: ACR TI-RADS provides effective stratification of cytological malignancy risk in TI-RADS 4–5 nodules. TI-RADS 5 is independently associated with Bethesda V–VI, while TI-RADS 4 demonstrates a high negative predictive value.

Article Details

References

1. Nguyễn Thị Chinh, Đỗ Trung Quân (2025), “Tỷ lệ ung thư tuyến giáp qua chọc hút tế bào kim nhỏ ở bệnh nhân có nhân giáp từ TIRADS 4 trở lên có yếu tố nguy cơ cao”, Tạp chí Y học Việt Nam, 546(3), tr. 95–99.
2. Nguyễn Thị Thu Thảo, Ngô Lê Lâm, Vũ Đăng Lưu (2019), “Nghiên cứu giá trị chẩn đoán ung thư tuyến giáp của phân độ EU-TIRADS 2017”, Điện quang Việt Nam, 33, tr. 12–18.
3. Ali S.Z., Baloch Z.W., Cochand-Priollet B., et al. (2023), “The 2023 Bethesda System for Reporting Thyroid Cytopathology”, Thyroid, 33(9), pp. 1039–1044.
4. Espinosa De Ycaza A.E., Lowe K.M., Dean D.S., et al. (2016), “Risk of malignancy in thyroid nodules with non-diagnostic fine-needle aspiration: a retrospective cohort study”, Thyroid, 26(11), pp. 1598–1604.
5. Haugen B.R., Alexander E.K., Bible K.C., et al. (2016), “2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer”, Thyroid, 26(1), pp. 1–133.
6. Middleton W.D., Teefey S.A., Reading C.C., et al. (2017), “Multiinstitutional analysis of thyroid nodule risk stratification using the American College of Radiology Thyroid Imaging Reporting and Data System”, AJR Am J Roentgenol, 208(6), pp. 1331–1341.
7. Tessler F.N., Middleton W.D., Grant E.G., et al. (2017), “ACR Thyroid Imaging, Reporting and Data System (TI-RADS): white paper of the ACR TI-RADS Committee”, J Am Coll Radiol, 14(5), pp. 587–595.